연구동향 분석
박사

Design of Live Attenuated Influenza Vaccine for Enhanced Safety : 인플루엔자생백신의 안전성증강을 위한 연구

Lee Yoon Jae 2016년

논문상세정보
인용/피인용
' Design of Live Attenuated Influenza Vaccine for Enhanced Safety : 인플루엔자생백신의 안전성증강을 위한 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 유인원
  • Cleavage site
  • Cold-adaptation
  • Hemagglutinin
  • Influenza virus
  • Live attenuated vaccine
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
48 0

0.0%

' Design of Live Attenuated Influenza Vaccine for Enhanced Safety : 인플루엔자생백신의 안전성증강을 위한 연구' 의 참고문헌

  • van de Sandt CE, Kreijtz JHCM, Rimmelzwaan GF. Evasion of Influenza A Viruses from Innate and Adaptive Immune Responses. Viruses-Basel. 2012;4(9):1438-76.
  • de Geus ED, Tefsen B, van Haarlem DA, van Eden W, van Die I, Vervelde L. Glycans from avian influenza virus are recognized by chicken dendritic cells and are targets for the humoral immune response in chicken. Molecular immunology. 2013;56(4):452-62.
  • Wang X, Li M, Zheng H, Muster T, Palese P, Beg AA, et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol. 2000;74(24):11566-73.
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med. 2006;354(13):1343-51.
  • Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. The New England journal of medicine. 2004;350(3):218-20.
  • Tharakaraman K, Raman R, Stebbins NW, Viswanathan K, Sasisekharan V, Sasisekharan R. Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. Sci Rep. 2013;3:1822. Epub 2013/05/11.
  • Suzuki Y, Ito T, Suzuki T, Holland RE, Chambers TM, Kiso M, et al. Sialic acid species as a determinant of the host range of influenza A viruses. J Virol. 2000;74(24):11825-31.
  • Sung JC, Van Wynsberghe AW, Amaro RE, Li WW, McCammon JA. Role of Secondary Sialic Acid Binding Sites in Influenza N1 Neuraminidase. J Am Chem Soc. 2010;132(9):2883-5.
  • Sun XM, Shi Y, Lu XS, He JH, Gao F, Yan JH, et al. Bat-Derived Influenza Hemagglutinin H17 Does Not Bind Canonical Avian or Human Receptors and Most Likely Uses a Unique Entry Mechanism. Cell Rep. 2013;3(3):769-78.
  • Sulli C, Banik SSR, Schilling J, Moser A, Xiang XX, Payne R, et al. Detection of Proton Movement Directly across Viral Membranes To Identify Novel Influenza Virus M2 Inhibitors. J Virol. 2013;87(19):10679-86.
  • Subbarao EK, Perkins M, Treanor JJ, Murphy BR. The Attenuation Phenotype Conferred by the M-Gene of the Influenza a/Ann-Arbor/6/60 Cold- Adapted Virus (H2n2) on the a/Korea/82 (H3n2) Reassortant Virus Results from a Gene Constellation Effect. Virus Res. 1992;25(1-2):37-50.
  • Su CY, Cheng TJR, Lin MI, Wang SY, Huang WI, Lin-Chu SY, et al. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. P Natl Acad Sci USA. 2010;107(45):19151-6.
  • Stech O, Veits J, Weber S, Deckers D, Schroer D, Vahlenkamp TW, et al. Acquisition of a Polybasic Hemagglutinin Cleavage Site by a Low-Pathogenic Avian Influenza Virus Is Not Sufficient for Immediate Transformation into a Highly Pathogenic Strain. J Virol. 2009;83(11):5864-8.
  • Sorenson JR, Campbell IR, Tepper LB, Lingg RD. Aluminum in the environment and human health. Environmental health perspectives. 1974;8:3-95.
  • Slepushkin AN, Obrosova-Serova NP, Burtseva EI, Rudenko LG, Govorkova EA, Vartanyan RV, et al. Comparison of live attenuated and inactivated influenza vaccines in schoolchildren in Russia: I. Safety and efficacy in two Moscow schools, 1987/88. Vaccine. 1993;11(3):323-8.
  • Skehel JJ, Cross K, Steinhauer D, Wiley DC. Influenza fusion peptides. Biochem Soc T. 2001;29:623-6.
  • Shaw MW, Arden NH, Maassab HF. New aspects of influenza viruses. Clinical microbiology reviews. 1992;5(1):74-92.
  • Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. Plos Pathog. 2008;4(6):e1000085.
  • Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, Park SJ, et al. Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, sialic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. Biochemistry. 1992;31(40):9609-21. Epub 1992/10/13.
  • Rao P, Yuan WM, Krug RM. Crucial role of CA cleavage sites in the cap-snatching mechanism for initiating viral mRNA synthesis. Embo J. 2003;22(5):1188-98.
  • Quan FS, Huang CZ, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81(7):3514-24.
  • Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-12. Epub 2004/07/21.
  • Perdue ML, Garcia M, Senne D. Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res. 1997;49(2):173-86.
  • Paterson D, Fodor E. Emerging Roles for the Influenza A Virus Nuclear Export Protein (NEP). Plos Pathog. 2012;8(12).
  • O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines. 2007;6(5):699- 710.
  • Noda T, Kawaoka Y. Packaging of influenza virus genome: Robustness of selection. P Natl Acad Sci USA. 2012;109(23):8797-8.
  • Nicholas R. Markham AW, Leslie S. Zuker, Michael Zuker The UNAFold Web Server.
  • Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine. 2003;21(16):1769-75.
  • Nayak DP, Hui EKW, Barman S. Assembly and budding of influenza virus. Virus Res. 2004;106(2):147-65.
  • Munster VJ, Schrauwen EJA, de Wit E, van den Brand JMA, Bestebroer TM, Herfst S, et al. Insertion of a Multibasic Cleavage Motif into the Hemagglutinin of a Low-Pathogenic Avian Influenza H6N1 Virus Induces a Highly Pathogenic Phenotype. J Virol. 2010;84(16):7953-60.
  • Moss WN, Dela-Moss LI, Priore SF, Turner DH. The influenza A segment 7 mRNA 3' splice site pseudoknot/hairpin family. RNA biology. 2012;9(11):1305-10.
  • Moncorge O, Long JS, Cauldwell AV, Zhou HB, Lycett SJ, Barclay WS. Investigation of Influenza Virus Polymerase Activity in Pig Cells. J Virol. 2013;87(1):384-94.
  • Martinez-Romero C, de Vries E, Belicha-Villanueva A, Mena I, Tscherne DM, Gillespie VL, et al. Substitutions T200A and E227A in the hemagglutinin of pandemic 2009 influenza A virus increase lethality but decrease transmission. J Virol. 2013;87(11):6507-11. Epub 2013/03/29.
  • Li XQ, Palese P. Characterization of the Polyadenylation Signal of Influenza-Virus Rna. J Virol. 1994;68(2):1245-9.
  • Lekcharoensuk P, Lager KM, Vemulapalli R, Woodruff M, Vincent AL, Richt JA. Novel swine influenza virus subtype H3N1, United States. Emerg Infect Dis. 2006;12(5):787-94. Epub 2006/05/18.
  • Lee KH, Seo SU, Song JM, Lee CM, Kim HA, Seong BL. Characterization of live influenza vaccine donor strain derived from coldadaptation of X-31 virus. Vaccine. 2006;24(11):1966-74.
  • Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert opinion on investigational drugs. 1998;7(9):1475-82.
  • Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res. 2009;143(2):140-6.
  • Jin H, Zhou H, Lu B, Kemble G. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J Virol. 2004;78(2):995-8. Epub 2003/12/25.
  • Jang YH, Byun YH, Lee DH, Lee KH, Lee YJ, Lee YH, et al. Coldadapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets. Vaccine. 2013. Epub 2013/01/15.
  • Jagger BW, Wise HM, Kash JC, Walters KA, Wills NM, Xiao YL, et al. An Overlapping Protein-Coding Region in Influenza A Virus Segment 3 Modulates the Host Response. Science. 2012;337(6091):199-204.
  • Isakova-Sivak I, Chen LM, Matsuoka Y, Voeten JT, Kiseleva I, Heldens JG, et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology. 2011;412(2):297-305. Epub 2011/02/15.
  • Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opin Virol. 2012;2(2):160-7.
  • Hutchinson EC, Fodor E. Transport of the Influenza Virus Genome from Nucleus to Nucleus. Viruses. 2013;5(10):2424-46.
  • Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000;97(11):6108-13. Epub 2000/05/10.
  • Helenius A. Virus entry: What has pH got to do with it? Nat Cell Biol. 2013;15(2):125.
  • Guarnaccia T, Carolan LA, Maurer-Stroh S, Lee RTC, Job E, Reading PC, et al. Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model. Plos Pathog. 2013;9(5).
  • Green MS, Block C, Rannon L. Immunogenicity of a single dose of trivalent influenza vaccine including A/Philippines (H3N2): results of a field trial. Journal of medical virology. 1986;19(2):161-6.
  • Gohrbandt S, Veits J, Hundt J, Bogs J, Breithaupt A, Teifke JP, et al. Amino acids adjacent to the haemagglutinin cleavage site are relevant for virulence of avian influenza viruses of subtype H5. J Gen Virol. 2011;92:51-9.
  • Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE, Durbin JE, et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998;252(2):324-30.
  • Gao YL, Wen ZY, Dong K, Zhong GX, Wang XM, Bu ZG, et al. Characterization of Immune Responses Induced by Immunization with the HA DNA Vaccines of Two Antigenically Distinctive H5N1 HPAIV Isolates. Plos One. 2012;7(7).
  • Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral research. 2013;100(2):567-74.
  • DeBorde DC, Donabedian AM, Herlocher ML, Naeve CW, Maassab HF. Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes. Virology. 1988;163(2):429-43.
  • Cox RJ, Brokstad KA, Ogra P. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59(1):1-15.
  • Bogs J, Veits J, Gohrbandt S, Hundt J, Stech O, Breithaupt A, et al. Highly Pathogenic H5N1 Influenza Viruses Carry Virulence Determinants beyond the Polybasic Hemagglutinin Cleavage Site. Plos One. 2010;5(7).
  • Beyer WEP, Palache AM, de Jong JC, Osterhaus ADME. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis. Vaccine. 2002;20(9-10):1340-53.
  • Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Reviews in medical virology. 2010;20(5):298-310. Epub 2010/07/16.
  • Bertram S, Glowacka I, Steffen I, Kuhl A, Pohlmann S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev Med Virol. 2010;20(5):298-310.
  • Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136(2):168-75.
  • Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J Virol. 2004;78(18):9605- 11. Epub 2004/08/28.